Novo Nordisk's semaglutide shortage officially concludes in the US, spelling major threat for weight loss drug compounders
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply squeeze on Novo Nordisk’s diabetes and obesity counterpa | The FDA has officially declared an end to the supply squeeze on Novo Nordisk’s GLP-1 drug semaglutide for diabetes and obesity in the U.
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...
Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...
The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...
Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.
Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback